Transparency website aims to improve
This article was originally published in The Silver Sheet
Executive Summary
After receiving 46 comments about its new transparency website, CDRH said it will implement certain recommendations to improve it. However, most responders to a survey on the website, launched April 19, said they found it to be very useful. The website now includes links to various device-related databases and the CDRH management directory, and includes information on topics such as health hazard evaluations and health risk assessments. It also recently added a chart that explains to manufacturers and patients how adverse events are processed by the agency. (See "1FDA To Manufacturers: Describe Adverse Events More Fully"
You may also be interested in...
FDA To Manufacturers: Describe Adverse Events More Fully
FDA URGES FIRMS TO COMPLETE ADVERSE EVENT REPORT NARRATIVES so the agency will better understand the nature of the incident. Meanwhile, a new chart designed by CDRH's Office of Surveillance & Biometrics describes what FDA does with the reports it receives
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.